Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Merrill Egorin

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Disorders

Neoplasms

Living Beings

Mice

Concepts & Ideas

Procedures

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Munster P N; Marchion D; Thomas S; Egorin M; Minton S; Springett G; Lee J-H; Simon G; Chiappori A; Sullivan D; Daud A
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.
Egorin Merrill J; Shah Dhvani D; Christner Susan M; Yerk Mara A; Komazec Kristin A; Appleman Leonard R; Redner Robert L; Miller Brian M; Beumer Jan H
Effect of a proton pump inhibitor on the pharmacokinetics of imatinib.
Pavlovsky Carolina; Egorin Merrill J; Shah Dhvani D; Beumer Jan H; Rogel Silvia; Pavlovsky Santiago
Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Merrill Egorin (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Munster P N; Marchion D; Thomas S; Egorin M; Minton S; Springett G; Lee J-H; Simon G; Chiappori A; Sullivan D; Daud A
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.
British journal of cancer 2009;101(7):1044-50.
2009: Egorin Merrill J; Shah Dhvani D; Christner Susan M; Yerk Mara A; Komazec Kristin A; Appleman Leonard R; Redner Robert L; Miller Brian M; Beumer Jan H
Effect of a proton pump inhibitor on the pharmacokinetics of imatinib.
British journal of clinical pharmacology 2009;68(3):370-4.
2009: Pavlovsky Carolina; Egorin Merrill J; Shah Dhvani D; Beumer Jan H; Rogel Silvia; Pavlovsky Santiago
Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia.
Pharmacotherapy 2009;29(9):1152-6.
2009: Baruchel Sylvain; Sharp Julia R; Bartels Ute; Hukin Juliette; Odame Isaac; Portwine Carol; Strother Doug; Fryer Chris; Halton Jackie; Egorin Merrill J; Reis Rui Manuel; Martinho Olga; Stempak Diana; Hawkins Cynthia; Gammon Janet; Bouffet Eric
A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours.
European journal of cancer (Oxford, England : 1990) 2009;45(13):2352-9.
2009: Badros Ashraf; Burger Angelika M; Philip Sunita; Niesvizky Ruben; Kolla Sarah S; Goloubeva Olga; Harris Carolynn; Zwiebel James; Wright John J; Espinoza-Delgado Igor; Baer Maria R; Holleran Julianne L; Egorin Merrill J; Grant Steven
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(16):5250-7.
2009: Parise Robert A; Egorin Merrill J; Christner Susan M; Shah Dhvani D; Zhou Wei; Beumer Jan H
A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(20-21):1894-900.
2009: Tange Yuichi; Kondo Akihide; Egorin Merrill J; Mania-Farnell Barbara; Daneriallis Georgy M; Nakazaki Hiromichi; Sredni Simone T; Rajaram Veena; Goldman Stewart; Soares Marcelo B; Tomita Tadanori
Interstitial continuous infusion therapy in a malignant glioma model in rats.
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2009;25(6):655-62.
2009: Park Deric M; Shah Dhvani D; Egorin Merrill J; Beumer Jan H
Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery.
Journal of neuro-oncology 2009;93(2):279-83.
2009: Fakih Marwan G; Pendyala Lakshmi; Fetterly Gerald; Toth Karoli; Zwiebel James A; Espinoza-Delgado Igor; Litwin Alan; Rustum Youcef M; Ross Mary Ellen; Holleran Julianne L; Egorin Merrill J
A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(9):3189-95.
2009: Reardon David A; Egorin Merrill J; Desjardins Annick; Vredenburgh James J; Beumer Jan H; Lagattuta Theodore F; Gururangan Sridharan; Herndon James E; Salvado August J; Friedman Henry S
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
Cancer 2009;115(10):2188-98.
2009: Guo Jianxia; Parise Robert A; Joseph Erin; Egorin Merrill J; Lazo John S; Prochownik Edward V; Eiseman Julie L
Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice.
Cancer chemotherapy and pharmacology 2009;63(4):615-25.
2009: Zeh Herbert J; Brown Charles K; Holtzman Matthew P; Egorin Merrill J; Holleran Julianne L; Potter Douglas M; Bartlett David L
A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer.
Annals of surgical oncology 2009;16(2):385-94.
2008: Rabik Cara A; Fishel Melissa L; Holleran Julianne L; Kasza Kristen; Kelley Mark R; Egorin Merrill J; Dolan M Eileen
Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress.
The Journal of pharmacology and experimental therapeutics 2008;327(2):442-52.
2008: Tse Archie N; Klimstra David S; Gonen Mithat; Shah Manish; Sheikh Tahir; Sikorski Rachel; Carvajal Richard; Mui Janet; Tipian Caroll; O'Reilly Eileen; Chung Ki; Maki Robert; Lefkowitz Robert; Brown Karen; Manova-Todorova Katia; Wu Nian; Egorin Merrill J; Kelsen David; Schwartz Gary K
A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(20):6704-11.
2008: Parise Robert A; Shawaqfeh Mohammad; Egorin Merrill J; Beumer Jan H
Liquid chromatography-mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;872(1-2):141-7.
2008: Morgan Mark A; Darcy Kathleen M; Rose Peter G; DeGeest Koen; Bookman Michael A; Aikins James K; Sill Michael W; Mannel Robert S; Allievi Cecilia; Egorin Merrill J;
Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group.
Gynecologic oncology 2008;110(3):329-35.
2008: Gamblin T Clark; Egorin Merrill J; Zuhowski Eleanor G; Lagattuta Theodore F; Herscher Laurie L; Russo Angelo; Libutti Steven K; Alexander H Richard; Dedrick Robert L; Bartlett David L
Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas.
Cancer chemotherapy and pharmacology 2008;62(4):647-53.
2008: Beumer Jan H; Eiseman Julie L; Parise Robert A; Florian Jeffry A; Joseph Erin; D'Argenio David Z; Parker Robert S; Kay Brittany; Covey Joseph M; Egorin Merrill J
Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.
Cancer chemotherapy and pharmacology 2008;62(3):457-64.
2008: Zamboni William C; Strychor Sandra; Joseph Erin; Parise Robert A; Egorin Merrill J; Eiseman Julie L
Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts.
Cancer chemotherapy and pharmacology 2008;62(3):417-26.
2008: Bernardi Ronald J; Bomgaars Lisa; Fox Elizabeth; Balis Frank M; Egorin Merrill J; Lagattuta Theodore F; Aikin Alberta; Whitcomb Patricia; Renbarger Jamie; Lieberman Frank S; Berg Stacey L; Blaney Susan M
Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis.
Cancer chemotherapy and pharmacology 2008;62(2):355-61.
2008: Beumer Jan H; Parise Robert A; Newman Edward M; Doroshow James H; Synold Timothy W; Lenz Heinz-Josef; Egorin Merrill J
Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).
Cancer chemotherapy and pharmacology 2008;62(2):363-8.
2008: Beumer Jan H; Eiseman Julie L; Parise Robert A; Joseph Erin; Covey Joseph M; Egorin Merrill J
Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3529-35.
2008: Ramalingam Suresh S; Egorin Merrill J; Ramanathan Ramesh K; Remick Scot C; Sikorski Rachel P; Lagattuta Theodore F; Chatta Gurkamal S; Friedland David M; Stoller Ronald G; Potter Douglas M; Ivy S Percy; Belani Chandra P
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3456-61.
2008: Reardon David A; Desjardins Annick; Vredenburgh James J; Sathornsumetee Sith; Rich Jeremy N; Quinn Jennifer A; Lagattuta Theodore F; Egorin Merrill J; Gururangan Sridharan; McLendon Roger; Herndon James E; Friedman Allan H; Salvado August J; Friedman Henry S
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Neuro-oncology 2008;10(3):330-40.
2008: Egorin Merrill J
Population pharmacokinetc/pharmacodynamic modeling of paclitaxel and carboplatin in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(8):2517; author reply 2517-8.
2008: Gibbons Joseph; Egorin Merrill J; Ramanathan Ramesh K; Fu Pingfu; Mulkerin Daniel L; Shibata Stephen; Takimoto Chris H M; Mani Sridhar; LoRusso Patricia A; Grem Jean L; Pavlick Anna; Lenz Heinz-Josef; Flick Susan M; Reynolds Sherrie; Lagattuta Theodore F; Parise Robert A; Wang Yanfeng; Murgo Anthony J; Ivy S Percy; Remick Scot C;
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):570-6.
2008: Ramanathan Ramesh K; Egorin Merrill J; Takimoto Chris H M; Remick Scot C; Doroshow James H; LoRusso Patricia A; Mulkerin Daniel L; Grem Jean L; Hamilton Anne; Murgo Anthony J; Potter Douglas M; Belani Chandra P; Hayes Michael J; Peng Bin; Ivy S Percy;
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):563-9.
2008: Parise Robert A; Beumer Jan H; Kangani Cyrous O; Holleran Julianne L; Eiseman Julie L; Smith Nicola F; Covey Joseph M; Perrine Susan P; Egorin Merrill J
Liquid chromatography-mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;862(1-2):168-74.
2008: Kosovec Juliann E; Egorin Merrill J; Gjurich Susanna; Beumer Jan H
Quantitation of 5-fluorouracil (5-FU) in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2008;22(2):224-30.
2007: Ali Yaqoob; Lin Yong; Gharibo Mecide M; Gounder Murugesan K; Stein Mark N; Lagattuta Theodore F; Egorin Merrill J; Rubin Eric H; Poplin Elizabeth A
Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(19):5876-82.
2007: Guo Jianxia; Parise Robert A; Joseph Erin; Lan Jing; Pan Su-Shu; Joo Beomjun; Egorin Merrill J; Wipf Peter; Lazo John S; Eiseman Julie L
Pharmacology and antitumor activity of a quinolinedione Cdc25 phosphatase inhibitor DA3003-1 (NSC 663284).
Anticancer research 2007;27(5A):3067-73.
2007: Blasdel Carolyn; Egorin Merrill J; Lagattuta Theodore F; Druker Brian J; Deininger Michael W
Therapeutic drug monitoring in CML patients on imatinib.
Blood 2007;110(5):1699-701; author reply 1701.
2007: Takimoto Chris H; Graham Martin A; Lockwood Graham; Ng Chee M; Goetz Andrew; Greenslade Dennis; Remick Scot C; Sharma Sunil; Mani Sridhar; Ramanathan Ramesh K; Synold Timothy W; Doroshow James H; Hamilton Anne; Mulkerin Daniel L; Ivy Percy; Egorin Merrill J; Grem Jean L
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(16):4832-9.
2007: Lewis Lionel D; Miller Antonius A; Rosner Gary L; Dowell Jonathan E; Valdivieso Manuel; Relling Mary V; Egorin Merrill J; Bies Robert R; Hollis Donna R; Levine Ellis G; Otterson Gregory A; Millard Frederick; Ratain Mark J;
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(11):3302-11.
2007: Ramalingam Suresh S; Parise Robert A; Ramanathan Ramesh K; Lagattuta Theodore F; Musguire Lori A; Stoller Ronald G; Potter Douglas M; Argiris Athanassios E; Zwiebel James A; Egorin Merrill J; Belani Chandra P
Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(12):3605-10.
2007: Eiseman Julie L; Guo Jianxia; Ramanathan Ramesh K; Belani Chandra P; Solit David B; Scher Howard I; Ivy S Percy; Zuhowski Eleanor G; Egorin Merrill J
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(7):2121-7.
2007: Russell M A; Carpenter M W; Akhtar M S; Lagattuta T F; Egorin M J
Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk.
Journal of perinatology : official journal of the California Perinatal Association 2007;27(4):241-3.
2007: Bagatell Rochelle; Gore Lia; Egorin Merrill J; Ho Richard; Heller Glenn; Boucher Nichole; Zuhowski Eleanor G; Whitlock James A; Hunger Stephen P; Narendran Aru; Katzenstein Howard M; Arceci Robert J; Boklan Jessica; Herzog Cynthia E; Whitesell Luke; Ivy S Percy; Trippett Tanya M
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1783-8.
2007: Solit David B; Ivy S Percy; Kopil Catherine; Sikorski Rachel; Morris Michael J; Slovin Susan F; Kelly W Kevin; DeLaCruz Anthony; Curley Tracy; Heller Glenn; Larson Steven; Schwartz Lawrence; Egorin Merrill J; Rosen Neal; Scher Howard I
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1775-82.
2007: Ramanathan Ramesh K; Egorin Merrill J; Eiseman Julie L; Ramalingam Suresh; Friedland David; Agarwala Sanjiv S; Ivy S Percy; Potter Douglas M; Chatta Gurkamal; Zuhowski Eleanor G; Stoller Ronald G; Naret Cynthia; Guo Jianxia; Belani Chandra P
Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1769-74.
2007: Sinai Parisa; Berg Rance E; Haynie J Marshall; Egorin Merrill J; Ilaria Robert L; Forman James
Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo.
Journal of immunology (Baltimore, Md. : 1950) 2007;178(4):2028-37.
2007: Mulligan Kathleen; Zackin Robert; Von Roenn Jamie H; Chesney Margaret A; Egorin Merrill J; Sattler Fred R; Benson Constance A; Liu Tun; Umbleja Triin; Shriver Sharon; Auchus Richard J; Schambelan Morris;
Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial.
The Journal of clinical endocrinology and metabolism 2007;92(2):563-70.
2007: Mani S; McDaid H M; Grossman A; Muggia F; Goel S; Griffin T; Colevas D; Horwitz S B; Egorin M J
Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(1):190-5.
2007: Parise Robert A; Egorin Merrill J; Eiseman Julie L; Joseph Erin; Covey Joseph M; Beumer Jan H
Quantitative determination of the cytidine deaminase inhibitor tetrahydrouridine (THU) in mouse plasma by liquid chromatography/electrospray ionization tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2007;21(13):1991-7.
2006: Beumer Jan H; Eiseman Julie L; Parise Robert A; Joseph Erin; Holleran Julianne L; Covey Joseph M; Egorin Merrill J
Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(24):7483-91.
2006: Beumer Jan H; Joseph Erin; Egorin Merrill J; Parker Robert S; D'argenio David Z; Covey Joseph M; Eiseman Julie L
A mass balance and disposition study of the DNA methyltransferase inhibitor zebularine (NSC 309132) and three of its metabolites in mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5826-33.
2006: Yang Zejia; Schumaker Lisa M; Egorin Merrill J; Zuhowski Eleanor G; Guo Zhongmin; Cullen Kevin J
Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5817-25.
2006: Parise Robert A; Egorin Merrill J; Kanterewicz Beatriz; Taimi Mohammed; Petkovich Martin; Lew April M; Chuang Samuel S; Nichols Mark; El-Hefnawy Talal; Hershberger Pamela A
CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer.
International journal of cancer. Journal international du cancer 2006;119(8):1819-28.
2006: Zamboni William C; Ramanathan Ramesh K; McLeod Howard L; Mani Sridhar; Potter Douglas M; Strychor Sandra; Maruca Lauren J; King Cristi R; Jung Laura L; Parise Robert A; Egorin Merrill J; Davis Todd A; Marsh Sharon
Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.
Investigational new drugs 2006;24(5):393-401.
2006: Wen Patrick Y; Yung W K Alfred; Lamborn Kathleen R; Dahia Patricia L; Wang Yanfeng; Peng Bin; Abrey Lauren E; Raizer Jeffrey; Cloughesy Timothy F; Fink Karen; Gilbert Mark; Chang Susan; Junck Larry; Schiff David; Lieberman Frank; Fine Howard A; Mehta Minesh; Robins H Ian; DeAngelis Lisa M; Groves Morris D; Puduvalli Vinay K; Levin Victor; Conrad Charles; Maher Elizabeth A; Aldape Kenneth; Hayes Michael; Letvak Laurie; Egorin Merrill J; Capdeville Renaud; Kaplan Richard; Murgo Anthony J; Stiles Charles; Prados Michael D
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(16):4899-907.
2006: Parise Robert A; Holleran Julianne L; Beumer Jan H; Ramalingam Suresh; Egorin Merrill J
A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006;840(2):108-15.
2006: Beumer Jan H; Natale James J; Lagattuta Theodore F; Raptis Anastasios; Egorin Merrill J
Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome.
Pharmacotherapy 2006;26(7):903-7.
2006: Faber Edgar; Nausová Jitka; Jarosová Marie; Egorin Merrill J; Holzerová Milena; Rozmanová Sárka; Maresová Ivana; Divoký Vladimír; Indrák Karel
Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing.
Leukemia & lymphoma 2006;47(6):1082-90.
2006: Ratain Mark J; Miller Antonius A; McLeod Howard L; Venook Alan P; Egorin Merrill J; Schilsky Richard L
The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(11 Pt 2):3612s-6s.
2006: Abbosh Phillip H; Montgomery John S; Starkey Jason A; Novotny Milos; Zuhowski Eleanor G; Egorin Merrill J; Moseman Annie P; Golas Adam; Brannon Kate M; Balch Curtis; Huang Tim H M; Nephew Kenneth P
Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
Cancer research 2006;66(11):5582-91.
2006: Zamboni William C; Goel Sanjay; Iqbal Tahir; Parise Robert A; Strychor Sandra; Repinski Trisha V W; Egorin Merrill J; Mani Sridhar
Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors.
Cancer chemotherapy and pharmacology 2006;57(5):631-9.
2006: Lichtman Stuart M; Hollis Donna; Miller Antonius A; Rosner Gary L; Rhoades Chris A; Lester Eric P; Millard Frederick; Byrd John; Cullinan Stephen A; Rosen D Marc; Parise Robert A; Ratain Mark J; Egorin Merrill J;
Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(12):1846-51.
2006: Ramanathan Ramesh K; Fakih Marwan; Mani Sridhar; Deutsch Melvin; Perez Raymond P; Ritter Mark A; Eiseman Julie L; Ivy S Percy; Trump Donald L; Belani Chandra P; Parise Robert A; Potter Douglas M; Egorin Merrill J
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers.
Cancer chemotherapy and pharmacology 2006;57(4):465-74.
2006: Brown Jason W; Christie Neil A; Evans Carol; Egorin Merrill J
Case 4. Pulmonary stent migration and ingestion in a lung cancer patient.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(9):1478-9.
2006: Egorin Merrill
The effects of organ dysfunction on drug dosing.
Clinical advances in hematology & oncology : H&O 2006;4(2):116-8.
2006: Beumer Jan H; Joseph Erin; Egorin Merrill J; Covey Joseph M; Eiseman Julie L
Quantitative determination of zebularine (NSC 309132), a DNA methyltransferase inhibitor, and three metabolites in murine plasma by high-performance liquid chromatography coupled with on-line radioactivity detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006;831(1-2):147-55.
2005: Reardon David A; Egorin Merrill J; Quinn Jennifer A; Rich Jeremy N; Gururangan Sridharan; Vredenburgh James J; Desjardins Annick; Sathornsumetee Sith; Provenzale James M; Herndon James E; Dowell Jeannette M; Badruddoja Michael A; McLendon Roger E; Lagattuta Theodore F; Kicielinski Kimberly P; Dresemann Gregor; Sampson John H; Friedman Allan H; Salvado August J; Friedman Henry S
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9359-68.
2005: Glaze Elizabeth R; Lambert Amy L; Smith Adaline C; Page John G; Johnson William D; McCormick David L; Brown Alan P; Levine Barry S; Covey Joseph M; Egorin Merrill J; Eiseman Julie L; Holleran Julianne L; Sausville Edward A; Tomaszewski Joseph E
Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance.
Cancer chemotherapy and pharmacology 2005;56(6):637-47.
2005: Laurie Nikia A; Gray Jonathan K; Zhang Jiakun; Leggas Mark; Relling Mary; Egorin Merrill; Stewart Clinton; Dyer Michael A
Topotecan combination chemotherapy in two new rodent models of retinoblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(20):7569-78.
2005: Komoroski Bernard J; Parise Robert A; Egorin Merrill J; Strom Stephen C; Venkataramanan Raman
Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 1):6972-9.
2005: Zamboni William C; Jung Laura L; Egorin Merrill J; Hamburger Deborah R; Joseph Erin; Jin Ruzhi; Strychor Sandra; Ramanathan Ramesh K; Eiseman Julie L
Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13):4867-74.
2005: Rao V Koneti; Knutsen Turid; Ried Thomas; Wangsa Darawalee; Flynn Bernard Mike; Langham Gregory; Egorin Merrill J; Cole Diane; Balis Frank; Steinberg Seth M; Bates Susan; Fojo Tito
The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration.
Mutation research 2005;583(2):105-19.
2005: Holleran Julianne L; Parise Robert A; Joseph Erin; Eiseman Julie L; Covey Joseph M; Glaze Elizabeth R; Lyubimov Alexander V; Chen Ya-Fei; D'Argenio David Z; Egorin Merrill J
Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(10):3862-8.
2005: Ramanathan Ramesh K; Trump Donald L; Eiseman Julie L; Belani Chandra P; Agarwala Sanjiv S; Zuhowski Eleanor G; Lan Jing; Potter Douglas M; Ivy S Percy; Ramalingam Sakkaraiappan; Brufsky Adam M; Wong Michael K K; Tutchko Susan; Egorin Merrill J
Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3385-91.
2005: Ramanathan Ramesh K; Ramalingam Sakkaraiappan; Egorin Merrill J; Belani Chandra P; Potter Douglas M; Fakih Marwan; Jung Laura L; Strychor Sandra; Jacobs Samuel A; Friedland David M; Shin Dong M; Chatta Gurkamal S; Tutchko Susan; Zamboni William C
Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.
Cancer chemotherapy and pharmacology 2005;55(4):354-60.
2005: Fishel Melissa L; Gamcsik Michael P; Delaney Shannon M; Zuhowski Eleanor G; Maher Veronica M; Karrison Theodore; Moschel Robert C; Egorin Merrill J; Dolan M Eileen
Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine.
Cancer chemotherapy and pharmacology 2005;55(4):333-42.
2005: Murren John; Modiano Manuel; Kummar Shivaani; Clairmont Caroline; Egorin Merrill; Chu Edward; Sznol Mario
A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer.
Investigational new drugs 2005;23(2):123-35.
2005: Chen Xueyu; Bies Robert R; Ramanathan Ramesh K; Zuhowski Eleanor G; Trump Donald L; Egorin Merrill J
Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies.
Cancer chemotherapy and pharmacology 2005;55(3):237-43.
2005: Koon Henry B; Bubley Glenn J; Pantanowitz Liron; Masiello David; Smith Brad; Crosby Katherine; Proper Joann; Weeden Will; Miller Thomas E; Chatis Pamela; Egorin Merrill J; Tahan Steven R; Dezube Bruce J
Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(5):982-9.
2005: Eiseman Julie L; Lan Jing; Lagattuta Theodore F; Hamburger Deborah R; Joseph Erin; Covey Joseph M; Egorin Merrill J
Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts.
Cancer chemotherapy and pharmacology 2005;55(1):21-32.
2005: Fishel Melissa L; Newell David R; Griffin Roger J; Davison Richard; Wang Lan-Zhen; Curtin Nicola J; Zuhowski Eleanor G; Kasza Kristen; Egorin Merrill J; Moschel Robert C; Dolan M Eileen
Effect of cell cycle inhibition on Cisplatin-induced cytotoxicity.
The Journal of pharmacology and experimental therapeutics 2005;312(1):206-13.
2004: Miller Antonius A; Rosner Gary L; Egorin Merrill J; Hollis Donna; Lichtman Stuart M; Ratain Mark J
Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8325-31.
2004: Jung Laura L; Ramanathan Ramesh K; Egorin Merrill J; Jin Ruzhi; Belani Chandra P; Potter Douglas M; Strychor Sandra; Trump Donald L; Walko Christine; Fakih Marwan; Zamboni William C
Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors.
Cancer chemotherapy and pharmacology 2004;54(6):487-96.
2004: Eiseman Julie L; Brown-Proctor Clive; Kinahan Paul E; Collins Jerry M; Anderson Lawrence W; Joseph Erin; Hamburger Deborah R; Pan Su-Shu; Mathis Chester A; Egorin Merrill J; Klecker Raymond W
Distribution of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil in mice bearing colorectal cancer xenografts: rationale for therapeutic use and as a positron emission tomography probe for thymidylate synthase.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(19):6669-76.
2004: Frye Reginald F; Fitzgerald Sara M; Lagattuta Theodore F; Hruska Matthew W; Egorin Merrill J
Effect of St John's wort on imatinib mesylate pharmacokinetics.
Clinical pharmacology and therapeutics 2004;76(4):323-9.
2004: Parise Robert A; Sparrow Barney R; Merrill John W; Grossi Irma M; Covey Joseph M; Peggins James O; Egorin Merrill J
Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of halofuginone in plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;810(1):35-40.
2004: Ramalingam Sakkaraiappan; Lagattuta Theodore F; Egorin Merrill J; Hayes Michael J; Ramanathan Ramesh K
Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans.
Pharmacotherapy 2004;24(9):1232-5.
2004: Warren Katherine; Gervais Anne; Aikin Alberta; Egorin Merrill; Balis Frank M
Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Cancer chemotherapy and pharmacology 2004;54(3):206-12.
2004: Zamboni William C; Jung Laura L; Egorin Merrill J; Potter Douglas M; Friedland David M; Belani Chandra P; Agarwala Sanjiv S; Wong Michael M W; Fakih Marwan; Trump Donald L; Jin Ruzhi; Strychor Sandra; Vozniak Michael; Troetschel Monica; Ramanathan Ramesh K
Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(15):5058-64.
2004: Wolff Nicholas C; Randle Dwight E; Egorin Merrill J; Minna John D; Ilaria Robert L
Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3528-34.
2004: Holleran Julianne L; Fourcade Julien; Egorin Merrill J; Eiseman Julie L; Parise Robert A; Musser Steven M; White Kevin D; Covey Joseph M; Forrest Gerald L; Pan Su-Shu
In vitro metabolism of the phosphatidylinositol 3-kinase inhibitor, wortmannin, by carbonyl reductase.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(5):490-6.
2004: Neville Kathleen; Parise Robert A; Thompson Patrick; Aleksic Alexander; Egorin Merrill J; Balis Frank M; McGuffey Leticia; McCully Cynthia; Berg Stacey L; Blaney Susan M
Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(7):2525-9.
2004: Zamboni William C; Gervais Anne C; Egorin Merrill J; Schellens Jan H M; Zuhowski Elleanor G; Pluim Dick; Joseph Erin; Hamburger Deborah R; Working Peter K; Colbern Gail; Tonda Margaret E; Potter Douglas M; Eiseman Julie L
Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
Cancer chemotherapy and pharmacology 2004;53(4):329-36.
2004: Day Roger S; Manning Brenda K; Garrott Denise; Brufsky Adam M; Baar Joseph; Egorin Merrill J; Shirey William E; Friedman Charles
Evaluation of the OncoTCap (Oncology Thinking Cap) simulation in teaching medical students about clinical trials: some successes and some surprises.
Journal of cancer education : the official journal of the American Association for Cancer Education 2004;19(3):149-55.
2003: Holleran Julianne L; Egorin Merrill J; Zuhowski Eleanor G; Parise Robert A; Musser Steven M; Pan Su-shu
Use of high-performance liquid chromatography to characterize the rapid decomposition of wortmannin in tissue culture media.
Analytical biochemistry 2003;323(1):19-25.
2003: Goel S; Bulgaru A; Hochster H; Wadler S; Zamboni W; Egorin M; Ivy P; Leibes L; Muggia F; Lockwood G; Harvey E; Renshaw G; Mani S
Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(11):1682-7.
2003: Takimoto Chris H; Remick Scot C; Sharma Sunil; Mani Sridhar; Ramanathan Ramesh K; Doroshow James H; Hamilton Anne; Mulkerin Daniel; Graham Martin; Lockwood Graham F; Ivy Percy; Egorin Merrill; Greenslade Denis; Goetz Andrew; Grem Jean L
Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group.
Seminars in oncology 2003;30(4 Suppl 15):20-5.
2003: Musser Steven M; Egorin Merrill J; Zuhowski Eleanor G; Hamburger Deborah R; Parise Robert A; Covey Joseph M; White Kevin D; Eiseman Julie L
Biliary excretion of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats.
Cancer chemotherapy and pharmacology 2003;52(2):139-46.
2003: Fishel Melissa L; Delaney Shannon M; Friesen Lindsay D; Hansen Ryan J; Zuhowski Eleanor G; Moschel Robert C; Egorin Merrill J; Dolan M Eileen
Enhancement of platinum-induced cytotoxicity by O6-benzylguanine.
Molecular cancer therapeutics 2003;2(7):633-40.
2003: Takimoto Chris H; Remick Scot C; Sharma Sunil; Mani Sridhar; Ramanathan Ramesh K; Doroshow James; Hamilton Anne; Mulkerin Daniel; Graham Martin; Lockwood Graham F; Ivy Percy; Egorin Merrill; Schuler Barbara; Greenslade Denis; Goetz Andrew; Knight Ronald; Thomas Rebecca; Monahan Brian P; Dahut William; Grem Jean L;
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(14):2664-72.
2003: Parise Robert A; Ramanathan Ramesh K; Hayes Michael J; Egorin Merrill J
Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;791(1-2):39-44.
2003: Xu Lu; Eiseman Julie L; Egorin Merrill J; D'Argenio David Z
Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice.
Journal of pharmacokinetics and pharmacodynamics 2003;30(3):185-219.
2003: Wolff Nicholas C; Richardson James A; Egorin Merrill; Ilaria Robert L
The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia.
Blood 2003;101(12):5010-3.
2003: Akerley Wallace; Herndon James E; Egorin Merrill J; Lyss Alan P; Kindler Hedy L; Savarese Dianne M; Sherman Carol A; Rosen D Marc; Hollis Donna; Ratain Mark J; Green Mark R
Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
Cancer 2003;97(10):2480-6.
2003: Laufer Menachem; Ramalingam Sakkaraiappan; Schoenberg Mark P; Haisfield-Wolf Mary Ellen; Zuhowski Eleanor G; Trueheart Irene N; Eisenberger Mario A; Nativ Ofer; Egorin Merrill J
Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):697-703.
2003: Rudin Charles M; Yang Zejia; Schumaker Lisa M; VanderWeele David J; Newkirk Kenneth; Egorin Merrill J; Zuhowski Eleanor G; Cullen Kevin J
Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance.
Cancer research 2003;63(2):312-8.
2003: Egorin Merrill J
Horseshoes, hand grenades, and body-surface area-based dosing: aiming for a target.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):182-3.
2003: Beer Tomasz M; Eilers Kristine M; Garzotto Mark; Egorin Merrill J; Lowe Bruce A; Henner W David
Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(1):123-8.
2003: Parise Robert A; Ramanathan Ramesh K; Zamboni William C; Egorin Merrill J
Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;783(1):231-6.
2002: Muindi Josephia R; Peng Yibing; Potter Douglas M; Hershberger Pamela A; Tauch Jil S; Capozzoli Mary Jo; Egorin Merrill J; Johnson Candace S; Trump Donald L
Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel.
Clinical pharmacology and therapeutics 2002;72(6):648-59.
2002: Logan Theodore F; Jadali Fayega; Egorin Merrill J; Mintun Mark; Sashin Donald; Gooding William E; Choi Yong; Bishop Harry; Trump Donald L; Gardner Diane; Kirkwood John; Vlock Daniel; Johnson Candace
Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial.
Cancer chemotherapy and pharmacology 2002;50(6):433-44.
2002: Zamboni William C; Gervais Anne C; Egorin Merrill J; Schellens Jan H M; Hamburger Deborah R; Delauter Brian J; Grim Amy; Zuhowski Eleanor G; Joseph Erin; Pluim Dick; Potter Douglas M; Eiseman Julie L
Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(9):2992-9.
2002: Matin Khalid; Egorin Merrill J; Ballesteros Michael F; Smith David C; Lembersky Barry; Day Roger S; Johnson Candace S; Trump Donald L
Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate.
Cancer chemotherapy and pharmacology 2002;50(3):179-85.
2002: Hershberger Pamela A; McGuire Terence F; Yu Wei-Dong; Zuhowski Eleanor G; Schellens Jan H M; Egorin Merrill J; Trump Donald L; Johnson Candace S
Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression.
Molecular cancer therapeutics 2002;1(10):821-9.
2002: Egorin Merrill J; Zuhowski Eleanor G; McCully Cynthia M; Blaney Susan M; Kerr Jody Z; Berg Stacey L; Balis Frank M
Pharmacokinetics of intrathecal gemcitabine in nonhuman primates.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2437-42.
2002: Tannock Ian F; Lee Carol M; Tunggal Jonathon K; Cowan David S M; Egorin Merrill J
Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(3):878-84.
2002: Hashash Ahmad; Kirkpatrick D Lynn; Egorin Merrill J; Block Lawrence H; Lazo John S
Normal-phase and stability-indicating reversed-phase high-performance liquid chromatographic methods for the determination of the novel antitumor agent: 1-methylpropyl-2-imidazolyldisulfide.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2002;768(2):239-46.
2002: Egorin Merrill J; Lagattuta Theodore F; Hamburger Deborah R; Covey Joseph M; White Kevin D; Musser Steven M; Eiseman Julie L
Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.
Cancer chemotherapy and pharmacology 2002;49(1):7-19.
2002: Calvert A H; Egorin M J
Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies.
European journal of cancer (Oxford, England : 1990) 2002;38(1):11-6.
2001: Stecklair K P; Hamburger D R; Egorin M J; Parise R A; Covey J M; Eiseman J L
Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats.
Cancer chemotherapy and pharmacology 2001;48(5):375-82.
2001: Olver I; Davy M; Lüftner D; Park S H; Egorin M; Ellis A; Webster L
A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer.
Cancer chemotherapy and pharmacology 2001;48(2):109-14.
2001: Zamboni W C; D'Argenio D Z; Stewart C F; MacVittie T; Delauter B J; Farese A M; Potter D M; Kubat N M; Tubergen D; Egorin M J
Pharmacodynamic model of topotecan-induced time course of neutropenia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2301-8.
2001: Kerr J Z; Berg S L; Dauser R; Nuchtern J; Egorin M J; McGuffey L; Aleksic A; Blaney S
Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates.
Cancer chemotherapy and pharmacology 2001;47(5):411-4.
2001: Egorin M J; Zuhowski E G; Rosen D M; Sentz D L; Covey J M; Eiseman J L
Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
Cancer chemotherapy and pharmacology 2001;47(4):291-302.
2001: Rosenthal D I; Lee J H; Sinard R; Yardley D A; Machtay M; Rosen D M; Egorin M J; Weber R S; Weinstein G S; Chalian A A; Miller L K; Frenkel E P; Carbone D P
Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1363-73.
2001: Zamboni W C; Lüftner D I; Egorin M J; Schweigert M; Sezer O; Richter T; Natale J J; Possinger K
The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(1):119-22.
2001: Papadopoulos K P; Egorin M J; Huang M; Troxel A B; Kaufman E; Balmaceda C M; Vahdat L T; Hesdorffer C S
The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer.
Cancer chemotherapy and pharmacology 2001;47(1):45-50.
2000: Parise R A; Miles D R; Egorin M J
Sensitive high-performance liquid chromatographic assay for motexafin gadolinium and motexafin lutetium in human plasma.
Journal of chromatography. B, Biomedical sciences and applications 2000;749(2):145-52.
2000: Patnaik A; Warner E; Michael M; Egorin M J; Moore M J; Siu L L; Fracasso P M; Rivkin S; Kerr I; Litchman M; Oza A M
Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(21):3677-89.
2000: Egorin M J
Adenosine triphosphate-binding cassette proteins and bioavailability: "we can pump you up (or out)".
Journal of the National Cancer Institute 2000;92(20):1628-9.
2000: Delauter B J; Ramanathan R K; Egorin M J; Stover L L; Zuhowski E G; Plunkett W; Zamboni W C
Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.
Pharmacotherapy 2000;20(10):1204-7.
2000: Zamboni W C; Egorin M J; Van Echo D A; Day R S; Meisenberg B R; Brooks S E; Doyle L A; Nemieboka N N; Dobson J M; Tait N S; Tkaczuk K H
Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(18):3288-94.
2000: Murren J R; DiStasio S A; Lorico A; McKeon A; Zuhowski E G; Egorin M J; Sartorelli A C; Rappa G
Phase I and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignancies.
Cancer journal (Sudbury, Mass.) 2000;6(4):256-65.
2000: Ain K B; Egorin M J; DeSimone P A
Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group.
Thyroid : official journal of the American Thyroid Association 2000;10(7):587-94.
2000: Venook A P; Egorin M J; Rosner G L; Hollis D; Mani S; Hawkins M; Byrd J; Hohl R; Budman D; Meropol N J; Ratain M J
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(14):2780-7.
2000: Suntharalingam M; Haas M L; Conley B A; Egorin M J; Levy S; Sivasailam S; Herman J M; Jacobs M C; Gray W C; Ord R A; Aisner J A; Van Echo D A
The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck.
International journal of radiation oncology, biology, physics 2000;47(1):49-56.
2000: Fracasso P M; Westervelt P; Fears C L; Rosen D M; Zuhowski E G; Cazenave L A; Litchman M; Egorin M J;
Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(5):1124-34.
2000: Muldoon L L; Pagel M A; Kroll R A; Brummett R E; Doolittle N D; Zuhowski E G; Egorin M J; Neuwelt E A
Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):309-15.
2000: Tkaczuk K H; Zamboni W C; Tait N S; Meisenberg B R; Doyle L A; Edelman M J; Hausner P F; Egorin M J; Van Echo D A
Phase I study of docetaxel and topotecan in patients with solid tumors.
Cancer chemotherapy and pharmacology 2000;46(6):442-8.
1999: Sparano J A; Speyer J; Gradishar W J; Liebes L; Sridhara R; Mendoza S; Fry D; Egorin M J
Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(3):880-6.
1999: Belani C P; Kearns C M; Zuhowski E G; Erkmen K; Hiponia D; Zacharski D; Engstrom C; Ramanathan R K; Capozzoli M J; Aisner J; Egorin M J
Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(2):676-84.
1999: Egorin M J; Zuhowski E G; Sentz D L; Dobson J M; Callery P S; Eiseman J L
Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agent.
Cancer chemotherapy and pharmacology 1999;44(4):283-94.
1999: Egorin M J; Yuan Z M; Sentz D L; Plaisance K; Eiseman J L
Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats.
Cancer chemotherapy and pharmacology 1999;43(6):445-53.
1999: Steller M A; Egorin M J; Trimble E L; Bartlett D L; Zuhowski E G; Alexander H R; Dedrick R L
A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer.
Cancer chemotherapy and pharmacology 1999;43(2):106-14.
1998: Lilenbaum R C; Miller A A; Batist G; Bernard S; Hollis D R; Rosner G L; Egorin M J; Schilsky R L; Ratain M J
Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3302-9.
1998: Sridhara R; Eisenberger M A; Sinibaldi V J; Reyno L M; Egorin M J
Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 1998;7(7):631-4.
1998: Egorin M J; Rosen D M; Wolff J H; Callery P S; Musser S M; Eiseman J L
Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations.
Cancer research 1998;58(11):2385-96.
1998: Venook A P; Egorin M J; Rosner G L; Brown T D; Jahan T M; Batist G; Hohl R; Budman D; Ratain M J; Kearns C M; Schilsky R L
Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1811-9.
1998: Bachur N R; Lun L; Sun P M; Trubey C M; Elliott E E; Egorin M J; Malkas L; Hickey R
Anthracycline antibiotic blockade of SV40 T antigen helicase action.
Biochemical pharmacology 1998;55(7):1025-34.
1998: Glantz M J; Cole B F; Recht L; Akerley W; Mills P; Saris S; Hochberg F; Calabresi P; Egorin M J
High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(4):1561-7.
1998: Conley B A; Egorin M J; Tait N; Rosen D M; Sausville E A; Dover G; Fram R J; Van Echo D A
Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(3):629-34.
1998: Egorin M J; Rosen D M; Sridhara R; Sensenbrenner L; Cottler-Fox M
Plasma concentrations and pharmacokinetics of dimethylsulfoxide and its metabolites in patients undergoing peripheral-blood stem-cell transplants.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(2):610-5.
1998: Egorin M J
Overview of recent topics in clinical pharmacology of anticancer agents.
Cancer chemotherapy and pharmacology 1998;42 Suppl():S22-30.
1997: Hafner R; Cohn J A; Wright D J; Dunlap N E; Egorin M J; Enama M E; Muth K; Peloquin C A; Mor N; Heifets L B
Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study Group.
American journal of respiratory and critical care medicine 1997;156(3 Pt 1):918-23.
1997: Timpone J G; Wright D J; Li N; Egorin M J; Enama M E; Mayers J; Galetto G
The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative.
AIDS research and human retroviruses 1997;13(4):305-15.
1997: Kearns C M; Egorin M J
Considerations regarding the less-than-expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy.
Seminars in oncology 1997;24(1 Suppl 2):S2-91-S2-96.
1997: Fujiwara Y; Takahashi T; Yamakido M; Ohune T; Tsuya T; Egorin M J
Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics.
Journal of the National Cancer Institute 1997;89(3):260-2.
1997: Li Y; MacKerell A D; Egorin M J; Ballesteros M F; Rosen D M; Wu Y Y; Blamble D A; Callery P S
Comparative molecular field analysis-based predictive model of structure-function relationships of polyamine transport inhibitors in L1210 cells.
Cancer research 1997;57(2):234-9.
1997: Egorin M J; Rosen D M; Benjamin S E; Callery P S; Sentz D L; Eiseman J L
In vitro metabolism by mouse and human liver preparations of halomon, an antitumor halogenated monoterpene.
Cancer chemotherapy and pharmacology 1997;41(1):9-14.
1997: Conley B A; Egorin M J; Sridhara R; Finley R; Hemady R; Wu S; Tait N S; Van Echo D A
Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics.
Cancer chemotherapy and pharmacology 1997;39(4):291-9.
1996: Glantz M J; Choy H; Akerley W; Kearns C M; Egorin M J; Rhodes C H; Cole B F
Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response.
Seminars in oncology 1996;23(6 Suppl 16):128-35.
1996: Glantz M J; Choy H; Kearns C M; Cole B F; Mills P; Zuhowski E G; Saris S; Rhodes C H; Stopa E; Egorin M J
Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(2):600-9.
1996: Simberkoff M S; Hartigan P M; Hamilton J D; Day P L; Diamond G R; Dickinson G M; Drusano G L; Egorin M J; George W L; Gordin F M; Hawkes C A; Jensen P C; Kilmas N G; Labriola A M; O'Brien W A; Oster C N; Weinhold K J; Wray N P; Pazner S B
Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996;11(2):142-50.
1996: Li Y; Eiseman J L; Sentz D L; Rogers F A; Pan S S; Hu L T; Egorin M J; Callery P S
Synthesis and antitumor evaluation of a highly potent cytotoxic DNA cross-linking polyamine analogue, 1,12-diaziridinyl-4,9-diazadodecane.
Journal of medicinal chemistry 1996;39(1):339-41.
1996: Egorin M J; Sentz D L; Rosen D M; Ballesteros M F; Kearns C M; Callery P S; Eiseman J L
Plasma pharmacokinetics, bioavailability, and tissue distribution in CD2F1 mice of halomon, an antitumor halogenated monoterpene isolated from the red algae Portieria hornemannii.
Cancer chemotherapy and pharmacology 1996;39(1-2):51-60.
1996: Hussein A M; Petros W P; Ross M; Vredenburgh J J; Affrontil M L; Jones R B; Shpall E J; Rubin P; Elkordy M; Gilbert C; Gupton C; Egorin M J; Soper J; Berchuck A; Clarke-Person D; Berry D A; Peters W P
A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies.
Cancer chemotherapy and pharmacology 1996;37(6):561-8.
1996: Eiseman J L; Yuan Z M; Eddington N D; Sentz D L; Callery P S; Egorin M J
Plasma pharmacokinetics and urinary excretion of the polyamine analogue 1, 19-bis(ethylamino)-5, 10, 15-triazanonadecane in CD2F1 mice.
Cancer chemotherapy and pharmacology 1996;38(1):13-20.
1996: Jodrell D I; Murray L S; Hawtof J; Graham M A; Egorin M J
A comparison of methods for limited-sampling strategy design using data from a phase I trial of the anthrapyrazole DuP-941.
Cancer chemotherapy and pharmacology 1996;37(4):356-62.
1995: Sridhara R; Eisenberger M A; Sinibaldi V J; Reyno L M; Egorin M J
Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(12):2944-53.
1995: Glantz M J; Choy H; Kearns C M; Akerley W; Egorin M J
Weekly, outpatient paclitaxel and concurrent cranial irradiation in adults with brain tumors: preliminary results and promising directions.
Seminars in oncology 1995;22(5 Suppl 12):26-32.
1995: Aisner J; Belani C P; Kearns C; Conley B; Hiponia D; Engstrom C; Zuhowski E; Egorin M J
Feasibility and pharmacokinetics of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer.
Seminars in oncology 1995;22(5 Suppl 12):17-21.
1995: Reyno L M; Egorin M J; Eisenberger M A; Sinibaldi V J; Zuhowski E G; Sridhara R
Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(9):2187-95.
1995: Glantz M J; Choy H; Kearns C M; Mills P C; Wahlberg L U; Zuhowski E G; Calabresi P; Egorin M J
Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors.
Journal of the National Cancer Institute 1995;87(14):1077-81.
1995: Kearns C M; Gianni L; Egorin M J
Paclitaxel pharmacokinetics and pharmacodynamics.
Seminars in oncology 1995;22(3 Suppl 6):16-23.
1995: Egorin M J
Further refinement of carboplatin dosing.
Journal of the National Cancer Institute 1995;87(8):555-7.
1995: Gianni L; Kearns C M; Giani A; Capri G; Viganó L; Lacatelli A; Bonadonna G; Egorin M J
Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(1):180-90.
1995: Erkmen K; Egorin M J; Reyno L M; Morgan R; Doroshow J H
Effects of storage on the binding of carboplatin to plasma proteins.
Cancer chemotherapy and pharmacology 1995;35(3):254-6.
1995: Conley B A; O'Hara S; Wu S; Melink T J; Parnes H; Pardoe E; Egorin M J; Van Echo D A
Phase I trial of chloroguinoxaline sulfonamide, with correlation of its pharmacokinetics and pharmacodynamics.
Cancer chemotherapy and pharmacology 1995;37(1-2):139-49.
1994: Egorin M J; Reyno L M; Canetta R M; Jodrell D I; Swenerton K D; Pater J L; Burroughs J N; Novak M J; Sridhara R
Modeling toxicity and response in carboplatin-based combination chemotherapy.
Seminars in oncology 1994;21(5 Suppl 12):7-19.
1994: Chang M J; Yu W D; Reyno L M; Modzelewski R A; Egorin M J; Erkmen K; Vlock D R; Furmanski P; Johnson C S
Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
Cancer research 1994;54(20):5380-6.
1994: Yuan Z M; Rosen D M; Egorin M J; Callery P S
Cytotoxic activity of N1- and N8-aziridinyl analogs of spermidine.
Biochemical pharmacology 1994;47(9):1587-92.
1994: Zuhowski E G; Gutheil J C; Egorin M J
Rapid and sensitive high-performance liquid chromatographic assay for novobiocin in human serum.
Journal of chromatography. B, Biomedical applications 1994;655(1):147-52.
1994: Klecker R W; Jamis-Dow C A; Egorin M J; Erkmen K; Parker R J; Stevens R; Collins J M
Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat.
Drug metabolism and disposition: the biological fate of chemicals 1994;22(2):254-8.
1994: Yuan Z M; Egorin M J; Rosen D M; Simon M A; Callery P S
Cellular pharmacology of N1- and N8-aziridinyl analogues of spermidine.
Cancer research 1994;54(3):742-8.
1994: Jodrell D I; Reyno L M; Sridhara R; Eisenberger M A; Tkaczuk K H; Zuhowski E G; Sinibaldi V J; Novak M J; Egorin M J
Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(1):166-75.
1994: Eiseman J L; Eddington N D; Leslie J; MacAuley C; Sentz D L; Zuhowski M; Kujawa J M; Young D; Egorin M J
Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice.
Cancer chemotherapy and pharmacology 1994;34(6):465-71.
1993: Leslie J; Kujawa J M; Eddington N; Egorin M; Eiseman J
Stability problems with taxol in mouse plasma during analysis by liquid chromatography.
Journal of pharmaceutical and biomedical analysis 1993;11(11-12):1349-52.
1993: Lichtman S M; Ratain M J; Van Echo D A; Rosner G; Egorin M J; Budman D R; Vogelzang N J; Norton L; Schilsky R L
Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
Journal of the National Cancer Institute 1993;85(16):1319-26.
1993: Reyno L M; Egorin M J; Canetta R M; Jodrell D I; Swenerton K D; Pater J L; Burroughs J N; Novak M J; Sridhara R
Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(6):1156-64.
1993: Heyman S N; Spokes K; Egorin M J; Epstein F H
Glycine reduces early renal parenchymal uptake of cisplatin.
Kidney international 1993;43(6):1226-8.
1993: Eisenberger M A; Reyno L M; Jodrell D I; Sinibaldi V J; Tkaczuk K H; Sridhara R; Zuhowski E G; Lowitt M H; Jacobs S C; Egorin M J
Suramin, an active drug for prostate cancer: interim observations in a phase I trial.
Journal of the National Cancer Institute 1993;85(8):611-21.
1993: Egorin M J
Cancer pharmacology in the elderly.
Seminars in oncology 1993;20(1):43-9.
1993: Harpalani A D; Snyder S W; Subramanyam B; Egorin M J; Callery P S
Alkylamides as inducers of human leukemia cell differentiation: a quantitative structure-activity relationship study using comparative molecular field analysis.
Cancer research 1993;53(4):766-71.
1993: Conley B A; Egorin M J; Whitacre M Y; Carter D C; Zuhowski E G; Van Echo D A
Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin.
Cancer chemotherapy and pharmacology 1993;33(2):107-12.
1993: Smith D C; Jodrell D I; Egorin M J; Ambinder R M; Zuhowski E G; Kreis W; Ellis P G; Trump D L
Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer.
Cancer chemotherapy and pharmacology 1993;31(5):363-8.
1992: Jodrell D I; Egorin M J; Canetta R M; Langenberg P; Goldbloom E P; Burroughs J N; Goodlow J L; Tan S; Wiltshaw E
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(4):520-8.
1992: Egorin M J; Jodrell D I
Utility of individualized carboplatin dosing alone and in combination regimens.
Seminars in oncology 1992;19(1 Suppl 2):132-8.
1992: Hamilton J D; Hartigan P M; Simberkoff M S; Day P L; Diamond G R; Dickinson G M; Drusano G L; Egorin M J; George W L; Gordin F M
A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study.
The New England journal of medicine 1992;326(7):437-43.
1992: Scher H I; Jodrell D I; Iversen J M; Curley T; Tong W; Egorin M J; Forrest A
Use of adaptive control with feedback to individualize suramin dosing.
Cancer research 1992;52(1):64-70.
1992: Musser S M; Pan S S; Egorin M J; Kyle D J; Callery P S
Alkylation of DNA with aziridine produced during the hydrolysis of N,N',N''-triethylenethiophosphoramide.
Chemical research in toxicology 1992;5(1):95-9.
1992: Vokes E E; Moormeier J A; Ratain M J; Egorin M J; Haraf D J; Mick R; Weichselbaum R R
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
Cancer chemotherapy and pharmacology 1992;29(3):178-84.
1992: Mortensen M E; Cecalupo A J; Lo W D; Egorin M J; Batley R
Inadvertent intrathecal injection of daunorubicin with fatal outcome.
Medical and pediatric oncology 1992;20(3):249-53.
1992: Conley B A; Egorin M J; Sinibaldi V; Sewack G; Kloc C; Roberts L; Zuhowski E G; Forrest A; Van Echo D A
Approaches to optimal dosing of hexamethylene bisacetamide.
Cancer chemotherapy and pharmacology 1992;31(1):37-45.
1991: Trump D L; Egorin M J; Forrest A; Willson J K; Remick S; Tutsch K D
Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(11):2027-35.
1991: Snyder S W; Egorin M J; Callery P S
Induction of human leukemia cell differentiation by regiospecifically acetylated spermidines.
Biochemical and biophysical research communications 1991;180(2):591-6.
1991: Dodion P F; de Valeriola D; Crespeigne N; Kantrowitz J D; Piccart M; Wery F; Kerger J; Egorin M J; Forrest A; Bachur N R
Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(8):589-96.
1991: Heyman S N; Rosen S; Silva P; Spokes K; Egorin M J; Epstein F H
Protective action of glycine in cisplatin nephrotoxicity.
Kidney international 1991;40(2):273-9.
1991: Cohen N A; Egorin M J; Snyder S W; Ashar B; Wietharn B E; Pan S S; Ross D D; Hilton J
Interaction of N,N',N''-triethylenethiophosphoramide and N,N',N''-triethylenephosphoramide with cellular DNA.
Cancer research 1991;51(16):4360-6.
1991: Conley B A; Sewack G F; Egorin M J; Subramanyam B; Page J G; Grieshaber C K
The effect of the monoamine oxidase inhibitor isocarboxazid on the canine metabolism of the cell-differentiating agent hexamethylene bisacetamide.
Cancer chemotherapy and pharmacology 1991;28(1):33-8.
1991: de Valeriola D L; Ross D D; Forrest A; Cuddy D P; Egorin M J
Use of plasma cytotoxic activity to model cytotoxic pharmacodynamics of anticancer drugs.
Cancer chemotherapy and pharmacology 1991;29(2):133-40.
1990: Conley B A; Egorin M J; Sinibaldi V; Van Echo D A
Tolerance of full dose menogaril (NSC 269148) in patients with abnormal hepatic and renal function.
Investigational new drugs 1990;8(4):365-7.
1990: Ratain M J; Schilsky R L; Conley B A; Egorin M J
Pharmacodynamics in cancer therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(10):1739-53.
1990: Gitterman S R; Drusano G L; Egorin M J; Standiford H C
Population pharmacokinetics of zidovudine. The Veterans Administration Cooperative Studies Group.
Clinical pharmacology and therapeutics 1990;48(2):161-7.
1990: Egorin M J; Snyder S W; Wietharn B E
Effects of ethanolamine and choline on thiotepa cellular accumulation and cytotoxicity in L1210 cells.
Cancer research 1990;50(14):4322-7.
1990: Egorin M J; Snyder S W
Characterization of nonexchangeable radioactivity in L1210 cells incubated with [14C]thiotepa: labeling of phosphatidylethanolamine.
Cancer research 1990;50(13):4044-9.
1990: Egorin M J
Phase I trials: a strategy of ongoing refinement.
Journal of the National Cancer Institute 1990;82(6):446-7.
1990: Egorin M J; Snyder S W; Pan S S; Daly C
Cellular transport and accumulation of thiotepa.
Seminars in oncology 1990;17(1 Suppl 3):7-17.
1990: Snyder S W; Egorin M J; Zuhowski E G; Schimpff E C; Callery P S
Effects of the monoamine oxidase inhibitor, tranylcypromine, on induction of HL60 cell differentiation by hexamethylene bisacetamide and N-acetyl-1,6-diaminohexane.
Cancer communications 1990;2(7):231-6.
1989: Belani C P; Egorin M J; Abrams J S; Hiponia D; Eisenberger M; Aisner J; Van Echo D A
A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(12):1896-902.
1989: Egorin M J; Snyder S W; Pan S S; Daly C
Cellular transport and accumulation of thiotepa in murine, human, and avian cells.
Cancer research 1989;49(20):5611-7.
1989: Stone M J; Klintmalm G; Polter D; Husberg B; Egorin M J
Neoadjuvant chemotherapy and orthotopic liver transplantation for hepatocellular carcinoma.
Transplantation 1989;48(2):344-7.
1989: Subramanyam B; Callery P S; Egorin M J; Snyder S W; Conley B A
An active, aldehydic metabolite of the cell-differentiating agent hexamethylene bisacetamide.
Drug metabolism and disposition: the biological fate of chemicals 1989;17(4):398-401.
1989: Conley B A; Forrest A; Egorin M J; Zuhowski E G; Sinibaldi V; Van Echo D A
Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).
Cancer research 1989;49(12):3436-40.
1989: Egorin M J; Forrest A; Belani C P; Ratain M J; Abrams J S; Van Echo D A
A limited sampling strategy for cyclophosphamide pharmacokinetics.
Cancer research 1989;49(11):3129-33.
1989: Van Echo D A; Egorin M J; Aisner J
The pharmacology of carboplatin.
Seminars in oncology 1989;16(2 Suppl 5):1-6.
1989: Horn T D; Beveridge R A; Egorin M J; Abeloff M D; Hood A F
Observations and proposed mechanism of N,N',N''-triethylenethiophosphoramide (thiotepa)-induced hyperpigmentation.
Archives of dermatology 1989;125(4):524-7.
1989: Subramanyam B; Callery P S; Geelhaar L A; Egorin M J
A cyclic imine intermediate in the in vitro metabolic conversion of 1,6-diaminohexane to 6-aminohexanoic acid and caprolactam.
Xenobiotica; the fate of foreign compounds in biological systems 1989;19(1):33-42.
1989: Lokich J J; Egorin M J; Cohen B E; Bern M M; Zipoli T E; Moore C
A phase I study of thiotepa administered by short-term and protracted continuous intravenous infusion.
Cancer 1989;63(1):46-50.
1989: Wadler S; Egorin M J; Zuhowski E G; Tortorello L; Salva K; Runowicz C D; Wiernik P H
Phase I clinical and pharmacokinetic study of thiotepa administered intraperitoneally in patients with advanced malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(1):132-9.
1988: Miller B; Tenenholz T; Egorin M J; Sosnovsky G; Rao N U; Gutierrez P L
Cellular pharmacology of N,N',N''-triethylene thiophosphoramide.
Cancer letters 1988;41(2):157-68.
1988: Snyder S W; Egorin M J; Geelhaar L A; Hamburger A W; Callery P S
Induction of differentiation of human promyelocytic leukemia cells (HL60) by metabolites of hexamethylene bisacetamide.
Cancer research 1988;48(13):3613-6.
1988: Ackland S P; Choi K E; Ratain M J; Egorin M J; Williams S F; Sinkule J A; Bitran J D
Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(7):1192-6.
1988: Egorin M J; Snyder S W; Cohen A S; Zuhowski E G; Subramanyam B; Callery P S
Metabolism of hexamethylene bisacetamide and its metabolites in leukemic cells.
Cancer research 1988;48(7):1712-6.
1988: Lee E J; Egorin M J; Van Echo D A; Cohen A E; Tait N; Schiffer C A
Phase I and pharmacokinetic trial of carboplatin in refractory adult leukemia.
Journal of the National Cancer Institute 1988;80(2):131-5.
1988: Conley B A; Egorin M J; Zuhowski E G; Sinibaldi V J; Peterson D E
Salivary concentrations of hexamethylene bisacetamide (HMBA) in patients receiving 5-day continuous infusions.
Cancer chemotherapy and pharmacology 1988;22(1):65-8.
1988: Conley B A; Callery P S; Egorin M J; Subramanyam B; Geelhaar L A; Pan S S
Involvement of monoamine oxidase and diamine oxidase in the metabolism of the cell differentiating agent hexamethylene bisacetamide (HMBA).
Life sciences 1988;43(9):793-800.
1988: Poirier M C; Egorin M J; Fichtinger-Schepman A M; Yuspa S H; Reed E
DNA adducts of cisplatin and carboplatin in tissues of cancer patients.
IARC scientific publications 1988;(89):313-20.
1987: Egorin M J; Zuhowski E G; Cohen A S; Geelhaar L A; Callery P S; Van Echo D A
Plasma pharmacokinetics and urinary excretion of hexamethylene bisacetamide metabolites.
Cancer research 1987;47(22):6142-6.
1987: Egorin M J; Conley B A; Forrest A; Zuhowski E G; Sinibaldi V; Van Echo D A
Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.
Cancer research 1987;47(22):6104-10.
1987: Oldfield E H; Clark W C; Dedrick R L; Egorin M J; Austin H A; DeVroom H D; Joyce K M; Doppman J L
Reduced systemic drug exposure by combining intraarterial cis-diamminedichloroplatinum(II) with hemodialysis of regional venous drainage.
Cancer research 1987;47(7):1962-7.
1987: Egorin M J; Zuhowski E G; Nayar M S; Callery P S
Gas chromatographic analysis of metabolites of the cell differentiating agent hexamethylene bisacetamide.
Journal of chromatography 1987;415(1):148-55.
1987: Egorin M J; Sigman L M; Van Echo D A; Forrest A; Whitacre M Y; Aisner J
Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
Cancer research 1987;47(2):617-23.
1986: Callery P S; Egorin M J; Geelhaar L A; Nayar M S
Identification of metabolites of the cell-differentiating agent hexamethylene bisacetamide in humans.
Cancer research 1986;46(10):4900-3.
1986: Cohen B E; Egorin M J; Kohlhepp E A; Aisner J; Gutierrez P L
Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites.
Cancer treatment reports 1986;70(7):859-64.
1986: Sigman L M; Van Echo D A; Egorin M J; Whitacre M Y; Aisner J
Phase I trial of menogaril administered as an intermittent daily infusion for 5 days.
Cancer treatment reports 1986;70(6):721-5.
1986: Egorin M J; Van Echo D A; Whitacre M Y; Forrest A; Sigman L M; Engisch K L; Aisner J
Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
Cancer research 1986;46(3):1513-20.
1986: Lee E J; Van Echo D A; Egorin M J; Nayar M S; Shulman P; Schiffer C A
Diaziquone given as a continuous infusion is an active agent for relapsed adult acute nonlymphocytic leukemia.
Blood 1986;67(1):182-7.
1986: Tchekmedyian N S; Egorin M J; Cohen B E; Kaplan R S; Poplin E; Aisner J
Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusion.
Cancer chemotherapy and pharmacology 1986;18(1):33-8.
1985: Egan P C; Costanza M E; Dodion P; Egorin M J; Bachur N R
Doxorubicin and cisplatin excretion into human milk.
Cancer treatment reports 1985;69(12):1387-89.
1985: Egorin M J; Van Echo D A; Olman E A; Whitacre M Y; Forrest A; Aisner J
Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum.
Cancer research 1985;45(12 Pt 1):6502-6.
1985: Dodion P; Egorin M J; Engisch K L; Bachur N R
Metabolism and disposition of menogaril (NSC 269148) in the rabbit.
Cancer research 1985;45(11 Pt 1):5352-7.
1985: Egorin M J; Cohen B E; Kohlhepp E A; Gutierrez P L
Gas-liquid chromatographic analysis of N,N',N''-triethylene thiophosphoramide and N,N',N''-triethylene phosphoramide in biological samples.
Journal of chromatography 1985;343(1):196-202.
1985: Gutierrez P L; Egorin M J; Davis T A; Bachur N R
Effects of ascorbic acid on biologically obtained diaziquone free radicals.
Biochemical pharmacology 1985;34(13):2394-7.
1985: Gutierrez P L; Fox B M; Mossoba M M; Egorin M J; Nakazawa H; Bachur N R
Electron spin resonance of electrochemically generated free radicals from diaziquone and its derivatives.
Biophysical chemistry 1985;22(1-2):115-23.
1985: Gutierrez P L; Egorin M J; Fox B M; Friedman R; Bachur N R
Cellular activation of diaziquone [2,5-diaziridinyl-3,6-bis (carboethoxyamino)-1,4-benzoquinone] to its free radical species.
Biochemical pharmacology 1985;34(9):1449-55.
1985: Egorin M J; Fox B M; Spiegel J F; Gutierrez P L; Friedman R D; Bachur N R
Cellular pharmacology in murine and human leukemic cell lines of diaziquone (NSC 182986).
Cancer research 1985;45(3):992-9.
1985: Jones J M; Olman E A; Egorin M J; Aisner J
A case report and description of the pharmacokinetic behavior of intrapleurally instilled etoposide.
Cancer chemotherapy and pharmacology 1985;14(2):172-4.
1985: Dodion P; Egorin M J; Riggs C E; Ferraro T A; Tamburini J M; Bachur N R
Comparative murine metabolism and disposition of class II anthracycline antibiotics.
Cancer chemotherapy and pharmacology 1985;15(2):153-60.
1985: Gutierrez P L; Cohen B E; Sosnovsky G; Davis T A; Egorin M J
On the search for new anticancer drugs 14: the plasma pharmacokinetics and tissue distribution of spin-labeled thio-TEPA (SL-O-TT).
Cancer chemotherapy and pharmacology 1985;15(3):185-91.
1984: Egorin M J; Van Echo D A; Tipping S J; Olman E A; Whitacre M Y; Thompson B W; Aisner J
Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.
Cancer research 1984;44(11):5432-8.
1984: Egorin M J; Akman S R; Gutierrez P L
Plasma pharmacokinetics and tissue distribution of thiotepa in mice.
Cancer treatment reports 1984;68(10):1265-8.
1984: Cohen B E; Egorin M J; Nayar M S; Gutierrez P L
Effects of pH and temperature on the stability and decomposition of N,N'N"-triethylenethiophosphoramide in urine and buffer.
Cancer research 1984;44(10):4312-6.
1984: Van Echo D A; Egorin M J; Whitacre M Y; Olman E A; Aisner J
Phase I clinical and pharmacologic trial of carboplatin daily for 5 days.
Cancer treatment reports 1984;68(9):1103-14.
1984: Egorin M J; Bellis E H; Salcman M; Collins J M; Spiegel J F; Bachur N R
The pharmacology of diaziquone given in intravenous or intracarotid infusion to normal and intracranial tumor-bearing puppies.
Journal of neurosurgery 1984;60(5):1005-13.
1984: Nakazawa H; Riggs C E; Egorin M J; Redwood S M; Bachur N R; Bhatnagar R; Ito Y
Continuous extraction of urinary anthracycline antitumor antibiotics with the horizontal flow-through coil planet centrifuge.
Journal of chromatography 1984;307(2):323-33.
1984: Dodion P; Chang B K; Egorin M J; Olman E A; Engisch K L; Bachur N R
The disposition of the new anthracycline antibiotic, menogarol, in mice.
Drug metabolism and disposition: the biological fate of chemicals 1984;12(3):365-70.
1984: Dodion P; Egorin M J; Tamburini J M; Riggs C E; Bachur N R
The murine metabolism and disposition of marcellomycin.
Drug metabolism and disposition: the biological fate of chemicals 1984;12(2):209-16.
1983: Kaye T S; Egorin M J; Riggs C E; Olman E A; Chou F T; Salcman M
The plasma pharmacokinetics and tissue distribution of dimethyl sulfoxide in mice.
Life sciences 1983;33(13):1223-30.
1983: Egorin M J; Clawson R E; Ross L A; Friedman R D; Reich S D; Pollak A; Bachur N R
Murine metabolism and disposition of iron:adriamycin complexes.
Cancer research 1983;43(7):3253-62.
1983: Egorin M J; Andrews P A; Nakazawa H; Bachur N R
Purification and characterization of aclacinomycin A and its metabolites from human urine.
Drug metabolism and disposition: the biological fate of chemicals 1983;11(2):167-71.
1983: Spiegel J F; Egorin M J; Collins J M; Lerner B D; Bachur N R
The murine disposition and pharmacokinetics of the antineoplastic agent, diaziquone (NSC 182986).
Drug metabolism and disposition: the biological fate of chemicals 1983;11(1):41-6.
1983: Gerad H; Egorin M J; Whitacre M; Van Echo D A; Aisner J
Renal failure and platinum pharmacokinetics in three patients treated with cis-diamminedichloroplatinum(II) and whole-body hyperthermia.
Cancer chemotherapy and pharmacology 1983;11(3):162-6.
1983: Fuks J Z; Egorin M J; Aisner J; Van Echo D A; Ostrow S; Bachur N R; Wiernik P H
Therapeutic efficacy and pharmacokinetics of vindesine and vindesine-cisplatin in previously treated patients with non-small cell lung carcinoma.
Cancer chemotherapy and pharmacology 1983;10(2):104-8.
1982: Egorin M J; Kaplan R S; Salcman M; Aisner J; Colvin M; Wiernik P H; Bachur N R
Cyclophosphamide plasma and cerebrospinal fluid kinetics with and without dimethyl sulfoxide.
Clinical pharmacology and therapeutics 1982;32(1):122-8.
1982: Felsted R L; Pokrywka G; Chen C; Egorin M J; Bachur N R
Radioimmunoassay and immunochemistry of Phaseolus vulgaris phytohemagglutinin: verification of isolectin subunit structures.
Archives of biochemistry and biophysics 1982;215(1):89-99.
1982: Andrews P A; Egorin M J; May M E; Bachur N R
Reversed-phase high-performance liquid chromatography analysis of 6-thioguanine applicable to pharmacologic studies in humans.
Journal of chromatography 1982;227(1):83-91.
1982: Konits P H; Egorin M J; Van Echo D A; Aisner J; Andrews P A; May M E; Bachur N R; Wiernik P H
Phase II evaluation and plasma pharmacokinetics of high-dose intravenous 6-thioguanine in patients with colorectal carcinoma.
Cancer chemotherapy and pharmacology 1982;8(2):199-203.
1982: Egorin M J; Van Echo D; Fox B M; Whitacre M; Bachur N R
Plasma kinetics of aclacinomycin A and its major metabolites in man.
Cancer chemotherapy and pharmacology 1982;8(1):41-6.
1981: Riggs C E; Egorin M J; Fuks J Z; Schnaper N; Duffey P; Colvin O M; Aisner J; Wiernik P H; Bachur N R
Initial observations on the effects of delta 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicin.
Journal of clinical pharmacology 1981;21(8-9 Suppl):90S-98S.
1981: Egorin M J; Clawson R E; Ross L A; Chou F T; Andrews P A; Bachur N R
Disposition and metabolism of adriamycin octanoylhydrazone (NSC 233853) in mice and rabbits.
Drug metabolism and disposition: the biological fate of chemicals 1981;9(3):240-5.
1981: Clawson R E; Egorin M J; Fox B M; Ross L A; Bachur N R
Hyperthermic modification of cyclophosphamide metabolism in rat hepatic microsomes and liver slices.
Life sciences 1981;28(10):1133-7.
1981: Ostrow S; Egorin M J; Hahn D; Markus S; Aisner J; Chang P; LeRoy A; Bachur N R; Wiernik P H
High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity.
Cancer treatment reports 1981;65(1-2):73-8.
1981: Fuks J Z; Egorin M J; Aisner J; Ostrow S S; Klein M E; Bachur N R; Colvin M; Wiernik P H
Cyclophosphamide and dimethylsulfoxide in the treatment of squamous carcinoma of the lung. Therapeutic efficacy, toxicity, and pharmacokinetics.
Cancer chemotherapy and pharmacology 1981;6(2):117-20.
1981: Felsted R L; Li J; Pokrywka G; Egorin M J; Spiegel J; Dale R M
Comparison of Phaseolus vulgaris cultivars on the basis of isolectin differences.
The International journal of biochemistry 1981;13(5):549-57.
1980: Egorin M J; Clawson R E; Cohen J L; Ross L A; Bachur N R
Cytofluorescence localization of anthracycline antibiotics.
Cancer research 1980;40(12):4669-76.
1980: Ostrow S; Egorin M J; Hahn D; Markus S; Leroy A; Chang P; Klein M; Bachur N R; Wiernik P H
Cis-Dichlorodiammine platinum and adriamycin therapy for advanced gynecological and genitourinary neoplasms.
Cancer 1980;46(8):1715-21.
1980: Egorin M J; Clawson R E; Ross L A; Chou F T; Andrews P A; Bachur N R
Disposition and metabolism of N,N-dimethyldaunorubicin and N,N-dimethyladriamycin in rabbits and mice.
Drug metabolism and disposition: the biological fate of chemicals 1980;8(5):353-62.
1980: Egorin M J; Clawson R E; Ross L A; Bachur N R
Cellular pharmacology of N,N-dimethyl daunorubicin and N,N-dimethyl adriamycin.
Cancer research 1980;40(6):1928-33.
1980: LeRoy A F; Wehling M; Gormley P; Egorin M; Ostrow S; Bachur N; Wiernik P
Quantitative changes in cis-dichlorodiammineplatinum(II) speciation in excreted urine with time after iv infusion in man: methods of analysis, preliminary studies, and clinical results.
Cancer treatment reports 1980;64(1):123-32.
1980: Ostrow S; Egorin M; Aisner J; Bachur N; Wiernik P H
High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy.
Cancer clinical trials 1980;3(1):23-7.
1979: Egorin M J; Clawson R E; Ross L A; Schlossberger N M; Bachur N R
Cellular accumulation and disposition of aclacinomycin A.
Cancer research 1979;39(11):4396-400.
1979: Egorin M J; Clawson R E; Cohen J L; Ross L A; Bachur N R
Cellular pharmacology of 7(R)-O-methylnogarol: a new anticancer agent.
The Journal of pharmacology and experimental therapeutics 1979;210(2):229-36.
1979: Egorin M J; Bachur S Z; Felsted R L; Leavitt R D; Bachur N R
Phaseolus vulgaris isolectin binding to human erythrocytes.
The Journal of biological chemistry 1979;254(3):894-8.
1978: Egorin M J; Litvin F; Felsted R L; Bachur N R
Phytohemagglutinin isolectin stimulation of human lympocytes cultured in serum free medium.
Life sciences 1978;23(3):237-45.
1978: Egorin M J; Odders R N; Sanel F T; Felsted R L; Bachur N R
Inhibitory effects of phytohemagglutinin isolectins L4 and E4 on L1210 cells.
Cancer research 1978;38(6):1677-87.
1978: Egorin M J; Felsted R L; Bachur N R
Salicylate effects on the response of human lymphocytes to phytohemagglutinin isolectins.
Clinical immunology and immunopathology 1978;10(1):1-10.
1977: Felsted R L; Egorin M J; Leavitt R D; Bachur N R
Recombinations of subunits of Phaseolus vulgaris isolectins.
The Journal of biological chemistry 1977;252(9):2967-71.
1977: Egorin M J; Felsted R L; Bachur N R
Phytohemagglutinin isolectin stimulation of glucose utilization by lymphocytes.
Life sciences 1977;20(2):351-7.
1976: Egorin M J; Trump D L; Wainwright C W
Quinacrine ochronosis and rheumatoid arthritis.
JAMA : the journal of the American Medical Association 1976;236(4):385-6.
1974: Egorin M J; Hildebrand R C; Cimino E F; Bachur N R
Cytofluorescence localization of adriamycin and daunorubicin.
Cancer research 1974;34(9):2243-5.
1973: Cradock J C; Egorin M J; Bachur N R
Daunorubicin biliary excretion and metabolism in the rat.
Archives internationales de pharmacodynamie et de thérapie 1973;202(1):48-61.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Merrill Egorin

Research Profile (preview)

Chemicals & Drugs

Disorders

Living Beings

Concepts & Ideas

Procedures

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Merrill Egorin (preview)

All Publications